Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated ...

Novel targeted therapies have become standard treatment for chronic lymphocytic leukemia due to their ability to delay progression of this slow-growing malignancy. Nevertheless, CLL remains incurable.

Pierluigi Porcu, MD, speaks to the considerations clinicians need to account for to balance cost, patient experience, and outcomes for those with chronic lymphocytic leukemia (CLL). As treatment ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

Chronic lymphocytic leukemia (CLL) accounts for 38% of all leukemia diagnoses. 1 Due to CLL’s prominence, the treatment landscape is continuing to evolve with combination therapies and various ...

Analysis of racial disparities accounting for treatment received in chronic lymphocytic leukemia: A real-world cohort analysis. Fixed-duration ibrutinib + venetoclax for first-line treatment of ...

Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does ...

Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in adults over 60, accounting for nearly a third of leukaemia cases in Western countries. In India, however, its prevalence is ...

Autoimmune diseases in patients with CLL are separate from CLL, which calls for different treatments. Autoimmune complications “occur very commonly for people with CLL,” which is important for ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...